Nanoscope Therapeutics Highlights Optogenetics for Inherited Retinal Diseases at Dry AMD Conference
For individuals and families navigating the challenges of inherited retinal diseases (IRDs), news of advancements in therapeutic development offers a beacon of hope. The scientific community continues to explore innovative approaches to restore vision, and recent presentations at the 4th Annual Dry AMD Therapeutic Development conference underscored progress in this vital area. Nanoscope Therapeutics, a company actively developing gene therapies for IRDs, showcased its work on optogenetics, a promising technology for vision restoration.
The conference, held in Boston, Massachusetts, from November 14-16, 2023, brought together various companies to share their latest research and data on dry age-related macular degeneration (AMD). Among the presenters was Dr. Samarendra Mohanty, President and Chief Scientific Officer of Nanoscope Therapeutics.
Dr. Mohanty participated in a panel discussion on November 15, 2023, focusing on the challenges of developing recognized disease models for dry AMD. The following day, November 16, 2023, he delivered a presentation on the potential of optogenetics to improve visual acuity in macular degeneration patients, drawing from proof-of-concept data obtained in humans. His presentation also delved into the platform's broader potential to treat various retinal degenerative conditions.
Nanoscope Therapeutics is a clinical-stage biotechnology company that develops gene therapies for inherited retinal diseases and age-related macular degeneration. Their approach centers on gene-agnostic, sight-restoring optogenetic therapies. This technology aims to restore vision by making retinal cells light-sensitive, even in cases of advanced photoreceptor loss, and is designed to be effective regardless of the specific gene mutation causing the IRD.
While the conference primarily focused on dry AMD, Nanoscope's discussions on optogenetics are highly relevant to the IRD community. The gene-agnostic nature of their optogenetic therapy, MCO-010, means it could potentially benefit a wide range of patients with different inherited retinal conditions, such as retinitis pigmentosa and Stargardt disease. This offers hope for individuals whose conditions currently lack specific gene-targeted treatments.
Akari Therapeutics also presented at the conference, with Chief Scientific Officer Miles Nunn presenting a poster on the pre-clinical development of PASylated®-Nomacopan for Geographic Atrophy (GA) secondary to dry AMD. This compound is in the final stages of pre-clinical development as a potential treatment for GA. It is important to note that Akari Therapeutics' primary focus has shifted to oncology, developing antibody-drug conjugates.
The ongoing research and discussions at events like the Dry AMD Therapeutic Development conference are crucial for advancing treatments for various retinal conditions. The insights shared by companies like Nanoscope Therapeutics highlight the continuous effort to bring innovative, vision-restoring therapies closer to patients.